Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Treatment for Pulmonary Fibrosis, Volume II"
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 31 May 2023 | Viewed by 1677
Special Issue Editors
Interests: Interstitial pneumonia; pulmonary infection
Special Issues, Collections and Topics in MDPI journals
Interests: sarcoidosis; interstitial lung disease; bronchoalveolar lavage; lymphangioleiomyomatosis; lung
Special Issue Information
Pulmonary fibrosis is characterized by the excessive deposition of extracellular matrices and destruction of the pulmonary parenchyma. The cause or contributing factor of pulmonary fibrosis is often unknown, and some diseases, including idiopathic pulmonary fibrosis, have poor prognosis despite treatment. Recently, progressive fibrosing interstitial lung disease (PF-ILD) or progressive pulmonary fibrosis (PPF) has been advocated to this phenotype, but there are many uncertainties and problems left to be resolved in the term “PF-ILD or PPF”.
This Special Issue, “Pulmonary Fibrosis: From Pathogenesis to Therapeutics”, aims to focus on novel approaches to the pathogenesis, diagnosis and therapeutics of pulmonary fibrosis at basic to clinical levels.
Prof. Dr. Hiroshi Mukae
Dr. Noriho Sakamoto
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- idiopathic pulmonary fibrosis
- anti-fibrotic drug
- progressive fibrosing interstitial lung disease
- interstitial lung disease
Related Special Issue
- Treatment for Pulmonary Fibrosis in Biomedicines (8 articles)